GDC-0941, an inhibitor of the phosphoinositide-3 kinase (PI3K) pathway, significantly reduced spreading and migration of four thyroid carcinoma cell lines in culture. Furthermore, oral administration of GDC-0941 to a mice model of follicular thyroid carcinoma decreased tumor growth and metastatic lung colonization. These results support the development of PI3K inhibitors to treat thyroid cancer.
ORIGINAL RESEARCH PAPER
Burrows, N. et al. GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1α (HIF-1α) pathways. J. Clin. Endocrinol. Metab. doi:10.1210/jc.2011-1426
Rights and permissions
About this article
Cite this article
PI3K inhibitor decreases metastatic behavior in thyroid cancer. Nat Rev Endocrinol 8, 4 (2012). https://doi.org/10.1038/nrendo.2011.200
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2011.200
